So what's new?
- Two experimental oral treatments for relapsing-remitting MS, which have been shown to significantly reduce relapse rates in clinical trials, are nearing market approval. If approved, cladribine and fingolimod could become the first-ever oral treatments for people with MS.
- The FDA approved Ampyra, a new oral drug to improve walking in people with all types of MS. Ampyra is the first drug ever approved specifically to treat an MS symptom.
Thanks to the efforts of MS activists, an additional $5 million was set aside for MS research out of the 2009 Department of Defense budget.
- Scientists studied abnormalities of blood outflow from the brain to the heart and found many people with MS had significant evidence of slowed or obstructed blood drainage. This could mean abnormal blood flow may actually set off an immune response consistent with MS.
What's new with you?